Lercanidipine Hcl Recordati Industria Chimica E Farmaceutica S.P.A.

Lercanidipine, the active ingredient in Lercanidipine Hcl Recordati Industria Chimica E Farmaceutica S.P.A., is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adult patients by relaxing vascular smooth muscle and lowering blood pressure.

GNH USA supplies Lercanidipine Hcl Recordati Industria Chimica E Farmaceutica S.P.A. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used in the management of high blood pressure conditions.

- Essential hypertension: reduces systolic and diastolic blood pressure to target levels. - Isolated systolic hypertension: lowers elevated systolic pressure, especially in older adults. - Cardiovascular risk management: contributes to overall risk reduction by maintaining controlled blood pressure.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: sensation of warmth and redness. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially after standing. - Tachycardia: increased heart rate. - Nasal congestion.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Angioedema: swelling of face, lips, or throat. - Myocardial infarction: rare but reported. - Hepatic enzyme elevation. - Severe skin reactions such as Stevens‑Johnson syndrome. - Arrhythmias: abnormal heart rhythms.

Before initiating therapy with lercanidipine, several safety considerations should be observed.

- Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Hepatic impairment: dose adjustment may be required in patients with liver dysfunction. - Elderly patients: start at the lowest effective dose and monitor closely. - Concomitant antihypertensives: watch for additive hypotensive effects. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Lercanidipine can interact with several drug classes, influencing its efficacy and safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): may increase plasma levels. - Grapefruit juice: can markedly raise drug concentration. - Other potent vasodilators: risk of severe hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect. - Beta‑blockers: additive blood pressure lowering. - Other calcium‑channel blockers: potential for cumulative cardiovascular effects. - NSAIDs: may blunt antihypertensive response. - Digoxin: monitor for altered serum levels.